Skip to main content
Clinical Trials/NCT02042456
NCT02042456
Terminated
Not Applicable

Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts

GE Healthcare1 site in 1 country124 target enrollmentApril 2014
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
GE Healthcare
Enrollment
124
Locations
1
Primary Endpoint
Abnormal interpretation rate
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

This study is investigating whether automated whole breast ultrasound can improve detection of cancer in breast cancer screening when used as a supplement to mammography or as a supplement to digital breast tomosynthesis

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
July 2015
Last Updated
10 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Able and willing to provide signed declaration of informed consent or have a legally authorized representative provide signed declaration of informed consent for participation in all study procedures;
  • Women aged ≥18 years at the time of enrollment;\*
  • Women with a previous determination of dense breasts determined by mammogram as heterogeneously dense or extremely dense;
  • At moderately increased or high risk (\>15% lifetime risk) for breast cancer based on meeting one or more of the ACS criteria 1:
  • AND Referred for screening mammography

Exclusion Criteria

  • Have been screened using any breast imaging technology in \<12 months immediately prior to enrollment;
  • Exhibit breast cancer symptoms according to assessment by the subject's health care provider within one year prior to enrollment;
  • Diagnosed with breast cancer, with or without metastasis, within one year prior to enrollment;
  • Are currently pregnant as determined per standard clinical practice at the investigational site;
  • Present with contraindications to any imaging examination required in the study protocol;
  • Have breast implants; OR
  • Are lactating.

Outcomes

Primary Outcomes

Abnormal interpretation rate

Time Frame: One Year

Abnormal interpretation rates for each modality (FFDM and DBT+V-Preview, with and without ABUS+V-Preview).

Secondary Outcomes

  • Sensitivity(One Year)
  • Specificity(One Year)
  • Cancer Rate(One Year)
  • Positive Predictive Value(One Year)
  • Negative Predictive Value(One Year)

Study Sites (1)

Loading locations...

Similar Trials